Document ID: chunk:federal_register_of_legislation:F2020L01391:reg:9:p2
Version: federal_register_of_legislation:F2020L01391
Segment Type: reg
Provision Reference: reg 9 (pt 2/3)
Character Range: 6346–9425

having an intervertebral disc prolapse causing spinal stenosis at the affected site at the time of the clinical onset of spinal adhesive arachnoiditis;
(17)      having sarcoidosis before the clinical onset of spinal adhesive arachnoiditis;
(18)      having severe spinal trauma involving the affected site within the ten years before the clinical worsening of spinal adhesive arachnoiditis;
Note: severe spinal trauma is defined in the Schedule 1 - Dictionary.
(19)      undergoing spinal surgery involving the affected site within the ten years before the clinical worsening of spinal adhesive arachnoiditis;
Note: Examples of spinal surgery include spinal fusion, laminectomy and discectomy.
(20)      having a lumboperitoneal shunt at the affected site at the time of the clinical worsening of spinal adhesive arachnoiditis;
(21)      having an epidural blood patch within the three months before the clinical worsening of spinal adhesive arachnoiditis;
(22)      having a myelogram involving an injection of oil-soluble intrathecal radiological contrast agent before the clinical worsening of spinal adhesive arachnoiditis;
(23)       having a myelogram involving an injection of water-soluble intrathecal radiological contrast agent from the specified list of radiological contrast agents within the ten years before the clinical worsening of spinal adhesive arachnoiditis;
Note: specified list of radiological contrast agents is defined in the Schedule 1 - Dictionary.
(24)      having an injection of Thorotrast (thorium dioxide suspension) into the subarachnoid space before the clinical worsening of spinal adhesive arachnoiditis;
(25)      having an in situ intrathecal drug delivery system at the affected site at the time of the clinical worsening of spinal adhesive arachnoiditis;
(26)      having intrathecal injection of methotrexate or cytosine arabinoside within the one year before the clinical worsening of spinal adhesive arachnoiditis;
(27)      having intrathecal injection of radioactive gold at the affected site before the clinical worsening of spinal adhesive arachnoiditis;
(28)      having an infection from the specified list of infections before the clinical worsening of spinal adhesive arachnoiditis;
Note: specified list of infections is defined in the Schedule 1 - Dictionary.
(29)      having a subarachnoid haemorrhage within the ten years before the clinical worsening of spinal adhesive arachnoiditis;
(30)      having a spinal subdural haematoma at the affected site within the two years before the clinical worsening of spinal adhesive arachnoiditis;
(31)      having ankylosing spondylitis involving the affected site before the clinical worsening of spinal adhesive arachnoiditis;
(32)      having an intervertebral disc prolapse causing spinal stenosis at the affected site at the time of the clinical worsening of spinal adhesive arachnoiditis;
(33)      having sarcoidosis before the clinical worsening of spinal adhesive arachnoiditis;
(34)      inability to obtain appropriate clinical management for spinal adhesive arachnoiditis.